 Home > Active Ingredient News > Study of Nervous System > JAMA Neurol: Suicide risk assessment for patients with 5 new anti-epileptic drugs (eslicarbazepine, perampanel, brivaracetam, cannabidiol and cenobamate)

JAMA Neurol: Suicide risk assessment for patients with 5 new anti-epileptic drugs (eslicarbazepine, perampanel, brivaracetam, cannabidiol and cenobamate)

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

ln 0 1

comprehensive research group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In 2008, the US Food and Drug Administration Bureau ( the FDA meta-analysis) controlled clinical trials based on 199 randomized, placebo, for 11 anti-Suicide risk warnings have been added to the instructions for epilepsy medications (asms), including: carbamazepine, fenacetin, gabapentin, lamotrigine, levetiracetam, pregabalin, tiagabine, topiramate, valproic acid Salt and levonisamide
.

In the meta-study, compared with placebo, the suicidal tendency of patients receiving the above-mentioned anti-epileptic drugs increased by 1.

Manage FDAResearchers in

Researchers collect clinical research data from PubMed on asms after 2008, keywords include epilepsy, anti-epileptic drugs, seizures, suicide, suicidal ideation and drug names, phase II-III randomized clinical trials for all adjuvant treatments of drug-resistant epilepsy The test results are subjected to a secondary safety analysis
.

The main endpoints of the study were suicidal behavior (overall suicide and thought suicide), attempted suicide, and completed suicide

A total of 5 newly listed asms drugs have been suicide risk assessments, including eslicarbazepine, perampanel, brivaracetam, cannabidiol and cenobamate
.

These drugs evaluated suicide rates in 17 randomized clinical trials involving 5996 patients, of which 4000 patients were treated with ASMs and 1996 patients were treated with placebo

There is no evidence that the five new drugs as a whole or individual drugs will increase the risk of suicidal ideation (the overall risk ratio of the drug to the placebo is 0.

Studies believe that among the five anti-epileptic drugs approved for marketing after 2008, there is no evidence that the above drugs increase the risk of suicide in patients with epilepsy
.

Among the five antiepileptic drugs approved for marketing after 2008, there is no evidence that the above drugs increase the risk of suicide in patients with epilepsy
.

Among the five antiepileptic drugs approved for marketing after 2008, there is no evidence that the above drugs increase the risk of suicide in patients with epilepsy

Original source:

Pavel Klein et al.

Suicidality Risk of Newer Antiseizure Medications A Meta-analysis JAMA Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.